GlassScriptPhysician profile
Naveen George
NPI 1114376498
$1,287.41
in general payments reported to CMS, 2019-2025
13 companies · $406 in 2025
The $406 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.81 · 2021: $92.96 · 2022: $13.67 · 2023: $390 · 2024: $355 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,150.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $857.80 | 2023-2025 | |
| Lundbeck LLC | $77.77 | 2021 | |
| Lilly USA, LLC | $72.73 | 2024-2025 | Amyvid, Kisunla |
| Alexion Pharmaceuticals, INC. | $57.67 | 2025 | Ultomiris |
| Amneal Pharmaceuticals LLC | $46.07 | 2025 | Brekiya |
| Pfizer INC. | $37.56 | 2025 | |
| Genentech USA, INC. | $25.08 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.29 | 2025 | Hyqvia |
| Neurelis, INC. | $21.19 | 2024 | Valtoco |
| Acadia Pharmaceuticals INC | $20.94 | 2025 | Nuplazid |
| Csl Behring | $18.40 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.72 | 2025 | Austedo Xr |
| Horizon Therapeutics Plc | $15.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveen George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.